A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
A phase 3 trial testing IMP4927 in ovarian cancer, active and no longer recruiting.
Overview
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer is a phase 3 interventional study registered as NCT04169997, led by Impact Therapeutics, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer. Planned enrolment is 404 participants (actual). The study started in 2019-12-24 and primary completion is expected in 2023-03-16. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialStudy of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialSHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialChiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.
- TrialHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares Ovarian cancer and the tag ctgov-ingest.